From company acquisitions to FDA nods, here are six key updates in orthobiologics since Oct. 4.

Acuitive Technologies earned FDA clearance for the Citrepore bioactive bone filler, the company said Nov. 12.

Biologics company Theradaptive's lead therapeutic, OsteoAdapt SP, has been featured in a preclinical spinal fusion study published in Spine, a prominent, peer-reviewed publication for spinal surgeons.

Spine biologics holds incredible potential if it can overcome obstacles related to disc anatomy, Ezriel Kornel, MD, said. 

CytexOrtho has earned FDA approval to begin a clinical trial evaluating the safety and efficacy of its absorbable hip implant in human patients, according to an Oct. 29 report from Mass Device.

Washington, D.C.-based Regenerative Orthopedics & Sports Medicine has partnered with the Orthobiologics Research Initiative to support nonsurgical orthopedic research aimed at treating partial-thickness rotator cuff tears using cutting-edge orthobiologic procedures.

Phoenix-based Full Circle Orthopedics is expanding its regenerative medicine program, according to an Oct. 22 news release. 

Since the start of 2023, several practices and health systems have added the Bridge-Enhanced ACL restoration procedure, which uses a patient's blood to help heal the injury.

Bone Biologics appointed Phillip Meikle to its board of directors, according to an Oct. 21 news release.

A woman is suing Elutia, formerly Aziyo Biologics, after contracting tuberculosis from a product used in an April 2021 spine surgery, The Atlanta Journal-Constitution reported Oct. 17.

Tetrous, a start-up focused on bone-to-tendon healing following orthopedic surgery, has earned a fourth patent related to its EnFix family of demineralized cortical bone fiber implants.

Here are five spine and orthopedic companies that specialize in regenerative medicine and biologic implants.

Regenity Biosciences earned FDA 510(k) clearance for RejuvaKnee, a collagen-based meniscus implant designed for reinforcement and repair of soft tissue injuries of the meniscus, the company said Oct. 8.

RTI Surgical, a healthcare biologics company, plans to acquire Collagen Solutions, according to an Oct. 7 news release.

From new research to FDA nods, here are six key updates in the spine and orthopedic regenerative medicine space since Sept. 1.

Amphix Bio earned FDA breakthrough device designation for a bone regeneration drug-device combination, according to an Oct. 3 news release.

Medical technology company Enovis is partnering with Ossium Health to distribute viable bone matrix allografts.

McAllen, Texas-based Altus Spine and Joint Pain Center partnered with Regenexx to provide noninvasive regenerative medicine services for orthopedic patients. 

Rion, a regenerative medicine company, named five leaders to its advisory board, according to a Sept. 25 news release.

Zetagen Therapeutics' ZetaFuse has potential to treat degenerative disc disease in patients with late-stage cancer, according to a case study in the Journal of the American Academy of Orthopaedic Surgeons.